Thus, we asked whether these pathways are operational in tumor cells by examining the anosmin-1-induced motility in the presence of specific inhibitors of FGFR1 (SU5402, FGFR1 ectodomain antibody) or uPA (amiloride, uPA antibody). This evidence concerns the gene PLAU and neoplasm.